PPADS tetrasodium salt
Cat. No. 0625
Chemical Name: Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium salt
Biological ActivityA non-selective P2 purinergic antagonist. Blocks recombinant P2X1, P2X2, P2X3, P2X5 (IC50 = 1 - 2.6 μM), native P2Y2-like (IC50 ~ 0.9 mM), and recombinant P2Y4 (IC50 ~ 15 mM) receptors. Delays onset of calcium responses to mild hypoosmotic stress in cortical slices. iso-PPADS (Cat. No. 0683) also available.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Lambrecht et al (1992) PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur.J.Pharmacol. 217 217. PMID: 1330591.
McLaren et al (1994) Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br.J.Pharmacol. 111 913. PMID: 8019769.
Ziganshin et al (1994) Selective antagonism by PPADS at P2x-purinoceptors in rabbit isolated blood vessels. Br.J.Pharmacol. 111 923. PMID: 8019770.
Ralevic and Burnstock (1998) Receptors for purines and pyrimidines. Pharmacol.Rev. 50 413. PMID: 9755289.
Thrane et al (2011) Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events elicited by cerebral edema. Proc.Natl.Acad.Sci.U S A 108 846. PMID: 21187412.
If you know of a relevant citation for this product please let us know.
Keywords: PPADS tetrasodium salt, supplier, P2, purinergic, antagonists, P2X, Receptors, Purinergic, P2Y, purinoceptors
Find multiple products by catalog number
New Products in this Area
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.